Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex

Acta Anaesthesiologica Scandinavica

Volumn 55, Issue 6, 2011, Pages 700-707

  Staals, Lonneke M ^a   Driessen, J J ^b   Van Egmond, J ^b   De Boer, H D ^c   Klimek, M ^d   Flockton, E A ^e   Snoeck, M M J ^f  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPOFOL; ROCURONIUM; SUGAMMADEX;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; ENDOTRACHEAL INTUBATION; HUMAN; KIDNEY FAILURE; MUSCLE TWITCH; NEUROMUSCULAR BLOCKING; NORMAL HUMAN; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TRAIN OF FOUR; TREATMENT RESPONSE;

ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; RECEPTORS, NICOTINIC; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79959833795     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2011.02448.x     Document Type: Article

References (39)

1. Bom A, Bradley M, Cameron K, Clark JK, van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed 2002; 41: 266-70.
2. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99: 632-7. (Pubitemid 37051978)
3. Gijsenbergh F, Ramael S, Houwing N, Van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703. (Pubitemid 41415517)
4. Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev 2009; 7: CD007362.
5. De Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107: 239-44. (Pubitemid 47196486)
6. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, Hermens Y, Mirakhur RK. Reversal of rocuronium- induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110: 284-94.
7. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogenson J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74.
8. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety and pharmacokinetics. Anesthesiology 2007; 106: 935-43. (Pubitemid 46684059)
9. Staals LM, Snoeck MMJ, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth 2008; 101: 492-7.
10. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg 1980; 59: 935-43. (Pubitemid 11205676)
11. Bowman WC. Neuromuscular block. Br J Pharmacol 2006; 147 (Suppl. 1): S277-86.
12. Jonsson FM, Dabrowski M, Eriksson LI. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology 2009; 110: 1244-52.
13. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogenson J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808. (Pubitemid 47063004)
14. Kopman AF, Yee PS, Neuman GG. Relationship of the trainof- four fade to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 1997; 86: 765-71. (Pubitemid 27174715)
15. Claudius C, Viby-Mogenson J. Acceleromyography for use in scientific and clinical practice: a systematic review of the evidence. Anesthesiology 2008; 108: 1117-40.
16. Capron F, Alla F, Hottier C, Meistelman C, Fuchs-Buder T. Can acceleromyography detect low levels of residual paralysis? A probability approach to detect amechanomyographic train-of-four ratio of 0.9. Anesthesiology 2004; 100: 1119-24. (Pubitemid 38541966)
17. Ali HH. Criteria of adequate clinical recovery from neuromuscular block. Anesthesiology 2003; 98: 1278-80. (Pubitemid 36520217)
18. Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332: 1691-9.
19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037-9. (Pubitemid 36520187)
21. Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, Kuylenstierna R. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87: 1035-43. (Pubitemid 27469300)
22. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 2000; 92: 977-84. (Pubitemid 30180973)
23. Ali HH, Savarese JJ, Lebowitz PW, Ramsay FM. Twitch, tetanus and train-of-four as indices of recovery from non-depolarizing neuromuscular blockade. Anesthesiology 1981; 54: 294-7. (Pubitemid 11147388)
24. Mc Coy EP, Connolly FM, Mirakhur RK, Loan PB, Paxton LD. Nondepolarizing neuromuscular blocking drugs and train-of-four fade. Can J Anaesth 1995; 42: 213-6.
25. O'Hara DA, Fragen RJ, Shanks CA. Reappearance of the train-of-four after neuromuscular blockade induced with tubocurarine, vecuronium or atracurium. Br J Anaesth 1986; 58: 1296-9. (Pubitemid 17178921)
26. Itoh H, Shibata K, Nitta S, Kobayashi T. Train-of-four fade and neuromuscular block in rats: a comparison between pancuronium, vecuronium, and rocuronium. Can J Anaesth 2000; 47: 950-5.
27. Suzuki T, Munakata K, Watanabe N, Fukano N, Saeki S, Ogawa S. Comparative fading responses induced by mivacurium, cisatracurium, and d-tubocurarine in the evoked muscular compound action potentials of the cat. J Anesth 2003; 17: 98-103. (Pubitemid 36850109)
28. Suzuki T, Nagai H, Katsumata N, Ogawa S, Suzuki H. Investigation of fading responses induced by non-depolarising muscle relaxants in the evoked EMG of the gastrocnemius muscle of the cat. Acta Anaesthesiol Scand 1999; 43: 658-62. (Pubitemid 29289294)
29. Bom AH, Thomson K. Effect of high doses of sugammadex on mouse hemi-diaphragm contractions during TOF stimulation. Anesthesiology 2006; 105: A110.
30. Waud BE, Waud DR. The relation between tetanic fade and receptor occlusion in the presence of competitive neuromuscular block. Anesthesiology 1971; 35: 456-64.
31. Vizi ES, Lendvai B. Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions. Pharmacol Ther 1997; 73: 75-89. (Pubitemid 27191612)
32. Fagerlund MJ, Eriksson LI. Current concepts in neuromuscular transmission. Br J Anaesth 2009; 103: 108-14.
33. Faria M, Oliveira L, Timoteo MA, Lobo MG, Correia-De-Sa P. Blockade of neuronal facilitatory nicotinic receptors containing alpha 3 beta 2 subunits contribute to tetanic fade in the rat isolated diaphragm. Synapse 2003; 49: 77-88. (Pubitemid 36702717)
34. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, Eriksson LI. Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology 2006; 105: 521-33. (Pubitemid 44310435)
35. Jonsson M, Dabrowski M, Gurley DA, Larsson O, Johnson EC, Fredholm BB, Eriksson LI. Activation and inhibition of human muscular and neuronal nicotinic acetylcholine receptors by succinylcholine. Anesthesiology 2006; 104: 724-33.
36. Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 1981; 55: 148-59. (Pubitemid 11034210)
37. Karatas Y, Ergun Y, Gocmen C, Secilmis A, Singirik E, Dikmen A, Baysal F. Possible postsynaptic action of aminoglycosides in the frog rectus abdominis. Acta Med Okayama 2000; 54: 49-56.
38. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth 1999; 83: 302-20. (Pubitemid 29361145)
39. Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 2010; 81: 850-7.